Review
. 2020 Jul; 3(3):445-453.
doi: 10.20517/cdr.2020.09.

Resistance to chemoimmunotherapy in non-small-cell lung cancer

Maximilian Johannes Hochmair 1 
Affiliations
  • PMID: 35582443
  •     61 References

Abstract

Recent clinical trials evaluating the combination of chemotherapy with immune checkpoint inhibition for the primary treatment of lung cancer showed increased progression-free and overall survival compared with chemotherapy alone. However, the combination of these two modalities is less than additive and the mechanisms of resistance to this therapeutic intervention are discussed here. So far, the conventional biomarkers for immunotherapy, namely programmed death-ligand 1 expression or tumor mutational burden are poor predictors of the efficacy of immunochemotherapy, and the optimal sequence of chemotherapy and immunotherapy has yet to be defined.

Keywords: Lung cancer; chemotherapy; immunotherapy combination; pembrolizumab; resistance.

Chemotherapeutic agent-mediated elimination of myeloid-derived suppressor cells.
Zibing Wang, Brian Till, Quanli Gao.
Oncoimmunology, 2017 Aug 16; 6(7). PMID: 28811975    Free PMC article.
Review.
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
Roy S Herbst, Paul Baas, +16 authors, Edward B Garon.
Lancet, 2015 Dec 30; 387(10027). PMID: 26712084
Highly Cited.
Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?
L Apetoh, S Ladoire, G Coukos, F Ghiringhelli.
Ann Oncol, 2015 Apr 30; 26(9). PMID: 25922066
Highly Cited. Review.
Therapeutic management options for stage III non-small cell lung cancer.
Stephanie M Yoon, Talha Shaikh, Mark Hallman.
World J Clin Oncol, 2017 Mar 02; 8(1). PMID: 28246582    Free PMC article.
Review.
Cost-effectiveness analysis of pembrolizumab plus chemotherapy with PD-L1 test for the first-line treatment of NSCLC.
Ning Wan, Tian-Tian Zhang, +7 authors, Jian Li.
Cancer Med, 2020 Jan 17; 9(5). PMID: 31945265    Free PMC article.
Fluctuation of systemic immunity in melanoma and implications for timing of therapy.
Alexey A Leontovich, Roxana S Dronca, +10 authors, Svetomir N Markovic.
Front Biosci (Elite Ed), 2011 Dec 29; 4(3). PMID: 22201928
Pembrolizumab for the treatment of non-small-cell lung cancer.
Edward B Garon, Naiyer A Rizvi, +25 authors, KEYNOTE-001 Investigators.
N Engl J Med, 2015 Apr 22; 372(21). PMID: 25891174
Highly Cited.
Gemcitabine depletes regulatory T-cells in human and mice and enhances triggering of vaccine-specific cytotoxic T-cells.
Lorna Rettig, Samuel Seidenberg, +4 authors, Steve Pascolo.
Int J Cancer, 2011 Jun 29; 129(4). PMID: 21710545
Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity.
W Joost Lesterhuis, Joanne Salmons, +6 authors, Richard A Lake.
PLoS One, 2013 Apr 30; 8(4). PMID: 23626745    Free PMC article.
Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients.
François Ghiringhelli, Cedric Menard, +7 authors, Bruno Chauffert.
Cancer Immunol Immunother, 2006 Sep 09; 56(5). PMID: 16960692
Highly Cited.
Novel chemotherapy regimens for advanced lung cancer: have we reached a plateau?
Panagiotis Baxevanos, Giannis Mountzios.
Ann Transl Med, 2018 Jun 05; 6(8). PMID: 29862228    Free PMC article.
Review.
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.
Padmanee Sharma, Siwen Hu-Lieskovan, Jennifer A Wargo, Antoni Ribas.
Cell, 2017 Feb 12; 168(4). PMID: 28187290    Free PMC article.
Highly Cited. Review.
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.
Mark A Socinski, Robert M Jotte, +18 authors, IMpower150 Study Group.
N Engl J Med, 2018 Jun 05; 378(24). PMID: 29863955
Highly Cited.
Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy.
Yiyi Yan, Anagha Bangalore Kumar, +4 authors, Haidong Dong.
Front Immunol, 2018 Aug 14; 9. PMID: 30100909    Free PMC article.
Highly Cited. Review.
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.
Matthew M Gubin, Xiuli Zhang, +24 authors, Robert D Schreiber.
Nature, 2014 Nov 28; 515(7528). PMID: 25428507    Free PMC article.
Highly Cited.
Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients.
Jesus Vera Aguilera, Jonas Paludo, +10 authors, Yiyi Yan.
Melanoma Res, 2020 May 15; 30(4). PMID: 32404734    Free PMC article.
Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis.
Alfredo Addeo, Giuseppe Luigi Banna, Giulio Metro, Massimo Di Maio.
Front Oncol, 2019 May 07; 9. PMID: 31058078    Free PMC article.
Highly Cited. Systematic Review.
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.
Dirk Schadendorf, F Stephen Hodi, +7 authors, Jedd D Wolchok.
J Clin Oncol, 2015 Feb 11; 33(17). PMID: 25667295    Free PMC article.
Highly Cited.
Immune checkpoint inhibitors and non-small-cell lung cancer management: 2018 update.
Omar Abdel-Rahman, Don Morris.
Immunotherapy, 2019 Feb 08; 11(3). PMID: 30730273
Global Cancer Incidence and Mortality Rates and Trends--An Update.
Lindsey A Torre, Rebecca L Siegel, Elizabeth M Ward, Ahmedin Jemal.
Cancer Epidemiol Biomarkers Prev, 2015 Dec 17; 25(1). PMID: 26667886
Highly Cited. Review.
Combined Checkpoint Inhibition and Chemotherapy: New Era of 1st-Line Treatment for Non-Small-Cell Lung Cancer.
Chongkai Wang, Prakash Kulkarni, Ravi Salgia.
Mol Ther Oncolytics, 2019 Apr 13; 13. PMID: 30976658    Free PMC article.
Review.
Immune-mediated mechanisms influencing the efficacy of anticancer therapies.
Seth B Coffelt, Karin E de Visser.
Trends Immunol, 2015 Apr 11; 36(4). PMID: 25857662
Review.
Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer.
Alessandro Leonetti, Birgit Wever, +5 authors, Elisa Giovannetti.
Drug Resist Updat, 2019 Oct 05; 46. PMID: 31585395
Review.
Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance.
Laurence Zitvogel, Lorenzo Galluzzi, Mark J Smyth, Guido Kroemer.
Immunity, 2013 Jul 31; 39(1). PMID: 23890065
Highly Cited. Review.
Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity.
Eiji Suzuki, Veena Kapoor, +2 authors, Steven M Albelda.
Clin Cancer Res, 2005 Sep 17; 11(18). PMID: 16166452
Highly Cited.
Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer.
Stephen V Liu, D Ross Camidge, +11 authors, John Powderly.
Eur J Cancer, 2018 Jul 28; 101. PMID: 30053670
Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
Urania Dafni, Zoi Tsourti, Katerina Vervita, Solange Peters.
Lung Cancer, 2019 Jul 20; 134. PMID: 31319971
Highly Cited. Systematic Review.
Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.
Naiyer A Rizvi, Matthew D Hellmann, +13 authors, Scott Antonia.
J Clin Oncol, 2016 Jun 30; 34(25). PMID: 27354481    Free PMC article.
Highly Cited.
Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy.
Oliver Kepp, Lorenzo Galluzzi, +7 authors, Guido Kroemer.
Cancer Metastasis Rev, 2011 Jan 21; 30(1). PMID: 21249425
Highly Cited. Review.
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.
Pei-Ling Chen, Whijae Roh, +41 authors, Jennifer A Wargo.
Cancer Discov, 2016 Jun 16; 6(8). PMID: 27301722    Free PMC article.
Highly Cited.
Combination Strategies on the Basis of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?
Meng Qiao, Tao Jiang, Shengxiang Ren, Caicun Zhou.
Clin Lung Cancer, 2017 Jul 19; 19(1). PMID: 28716463
Review.
Impact of systemic therapy on circulating leukocyte populations in patients with metastatic breast cancer.
Anna-Maria Larsson, Anna Roxå, Karin Leandersson, Caroline Bergenfelz.
Sci Rep, 2019 Sep 19; 9(1). PMID: 31530882    Free PMC article.
Current Clinical Progress of PD-1/PD-L1 Immunotherapy and Potential Combination Treatment in Non-Small Cell Lung Cancer.
Jia-Xin Li, Ju-Min Huang, +4 authors, Pei-Yu Yan.
Integr Cancer Ther, 2019 Dec 17; 18. PMID: 31838881    Free PMC article.
Review.
Effect and biomarker of Nivolumab for non-small-cell lung cancer.
Li Wang, Deze Zhao, +2 authors, Xiaochun Zhang.
Biomed Pharmacother, 2019 Aug 08; 117. PMID: 31387181
Review.
Atezolizumab: feasible second-line therapy for patients with non-small cell lung cancer? A review of efficacy, safety and place in therapy.
Fanny Jean, Pascale Tomasini, Fabrice Barlesi.
Ther Adv Med Oncol, 2018 Feb 17; 9(12). PMID: 29449897    Free PMC article.
Review.
Biomarkers of response to PD-1/PD-L1 inhibition.
Saman Maleki Vareki, Carmen Garrigós, Ignacio Duran.
Crit Rev Oncol Hematol, 2017 Jul 12; 116. PMID: 28693793
Highly Cited. Review.
How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer.
S Peters, M Reck, +2 authors, M D Hellmann.
Ann Oncol, 2019 Mar 27; 30(6). PMID: 30912805
Review.
CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy.
Yiyi Yan, Siyu Cao, +12 authors, Haidong Dong.
JCI Insight, 2018 Apr 20; 3(8). PMID: 29669928    Free PMC article.
Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice.
W Joost Lesterhuis, Cornelis J A Punt, +11 authors, I Jolanda M de Vries.
J Clin Invest, 2011 Jul 19; 121(8). PMID: 21765211    Free PMC article.
Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations.
Martin Reck, Geetha Shankar, +5 authors, Alan Sandler.
Expert Rev Respir Med, 2019 Dec 13; 14(2). PMID: 31829747
Review.
Checkpoint inhibitors plus chemotherapy for first-line treatment of advanced non-small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials.
Aung Myint Tun, Kyaw Zin Thein, Wai Lin Thein, Elizabeth Guevara.
Future Sci OA, 2019 Oct 15; 5(9). PMID: 31608159    Free PMC article.
Review.
Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial.
M Reck, I Bondarenko, +7 authors, T J Lynch.
Ann Oncol, 2012 Aug 04; 24(1). PMID: 22858559
Highly Cited.
Treg-mediated acquired resistance to immune checkpoint inhibitors.
Reem Saleh, Eyad Elkord.
Cancer Lett, 2019 May 13; 457. PMID: 31078738
Review.
Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy.
Christina Pfirschke, Camilla Engblom, +18 authors, Mikael J Pittet.
Immunity, 2016 Feb 14; 44(2). PMID: 26872698    Free PMC article.
Highly Cited.
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.
Louis Fehrenbacher, Alexander Spira, +16 authors, POPLAR Study Group.
Lancet, 2016 Mar 14; 387(10030). PMID: 26970723
Highly Cited.
Dose-dense chemotherapy improves mechanisms of antitumor immune response.
Chih-Long Chang, Yun-Ting Hsu, +5 authors, Chien-Fu Hung.
Cancer Res, 2012 Oct 31; 73(1). PMID: 23108141    Free PMC article.
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.
Corey J Langer, Shirish M Gadgeel, +17 authors, KEYNOTE-021 investigators.
Lancet Oncol, 2016 Oct 18; 17(11). PMID: 27745820    Free PMC article.
Highly Cited.
Remarkable response of nivolumab-refractory lung cancer to salvage chemotherapy.
Daiki Ogawara, Hiroshi Soda, +4 authors, Hiroshi Mukae.
Thorac Cancer, 2017 Oct 25; 9(1). PMID: 29063735    Free PMC article.
The interaction of immune checkpoint inhibitor plus chemotherapy in non-small-cell lung cancer: subadditivity, additivity or synergism?
Elie Rassy, Ziad Bakouny, +2 authors, Nicholas Pavlidis.
Immunotherapy, 2019 Jun 13; 11(10). PMID: 31188048
Review.
Genetic evolution of T-cell resistance in the course of melanoma progression.
Antje Sucker, Fang Zhao, +16 authors, Annette Paschen.
Clin Cancer Res, 2014 Oct 09; 20(24). PMID: 25294904    Free PMC article.
Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer.
Song Ee Park, Se Hoon Lee, +3 authors, Jong-Mu Sun.
J Thorac Oncol, 2017 Nov 05; 13(1). PMID: 29101058
Highly Cited.
Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer.
Barbara Melosky, Rosalyn Juergens, +5 authors, Quincy Chu.
Oncologist, 2019 May 30; 25(1). PMID: 31138727    Free PMC article.
Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents.
Lorenzo Galluzzi, Aitziber Buqué, +2 authors, Guido Kroemer.
Cancer Cell, 2015 Dec 19; 28(6). PMID: 26678337
Highly Cited. Review.
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
Leena Gandhi, Delvys Rodríguez-Abreu, +27 authors, KEYNOTE-189 Investigators.
N Engl J Med, 2018 Apr 17; 378(22). PMID: 29658856
Highly Cited.
Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses.
W M Liu, D W Fowler, P Smith, A G Dalgleish.
Br J Cancer, 2009 Dec 10; 102(1). PMID: 19997099    Free PMC article.
Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication.
Ruth Ganss, Eduard Ryschich, +2 authors, Günter J Hämmerling.
Cancer Res, 2002 Mar 13; 62(5). PMID: 11888921
Highly Cited.
Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy.
Junjie Wu, David J Waxman.
Cancer Lett, 2018 Feb 08; 419. PMID: 29414305    Free PMC article.
Review.
Combination chemotherapy and immunotherapy in metastatic non-small cell lung cancer: a setback for personalized medicine?
Monica S Chatwal, Tawee Tanvetyanon.
Transl Lung Cancer Res, 2018 Nov 06; 7(Suppl 3). PMID: 30393603    Free PMC article.
Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2'-deoxycytidine treatment.
A Serrano, S Tanzarella, +4 authors, F Garrido.
Int J Cancer, 2001 Oct 23; 94(2). PMID: 11668505
Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape.
K A Olaussen, S Postel-Vinay.
Ann Oncol, 2016 Oct 30; 27(11). PMID: 27502726
Review.
Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer.
Joseph McLaughlin, Gang Han, +7 authors, David L Rimm.
JAMA Oncol, 2015 Nov 13; 2(1). PMID: 26562159    Free PMC article.
Highly Cited.